"It is a great honor to receive the prestigious Prix Galien," commented Marc Oczachowsky, EDAP TMS Chief Executive Officer. "This award recognizes the therapeutic excellence of our Focal One HIFU system as an innovative device in the treatment of localized prostate cancer. It also rewards the outstanding work achieved by our dedicated teams and partners in developing and bringing to market this minimally invasive therapy preserving prostate cancer patients' quality of life. We are very proud to be part of the highly selective group of companies awarded with the prestigious Prix Galien."
The jury reviewed 120 candidates and selected nominees among six categories. Awards were announced during the prestigious Galien gala dinner which took place on December 7, 2016 at the Pavillon d'Armenonville in Paris, France.